TSW
KIN

Thompson Siegel & Walmsley’s Kindred Biosciences, Inc. KIN Stock Holding History

Thompson Siegel & Walmsley’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-23,162
Closed -$214K – 726
2014
Q3 		$214K Buy
23,162
+8,262
+55% +$112K ﹤0.01% 374
2014
Q2 		$278K Buy
14,900
+5,400
+57% +$91.7K 0.01% 361
2014
Q1 		$176K Buy
+9,500
New +$181K ﹤0.01% 390

Other funds holding KIN

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Thompson Siegel & Walmsley's KIN Position: Q4 2014 in Review

Thompson Siegel & Walmsley sold out of Kindred Biosciences, Inc. (KIN) in Q4 2014, closing a stake of 23,162 shares — an estimated $214K sold.

Thompson Siegel & Walmsley first reported a position in KIN in Q1 2014 and held it in 3 quarters. The position peaked at $278K in Q2 2014. 64 funds tracked by Wall St. Rank hold KIN as of Q4 2014.

  • Thompson Siegel & Walmsley reported no remaining Kindred Biosciences, Inc. position as of Q4 2014 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 23,162 Kindred Biosciences, Inc. shares in Q4 2014, an estimated $214K.
  • Thompson Siegel & Walmsley first reported a position in Kindred Biosciences, Inc. in Q1 2014 and held it in 3 quarters.
  • Thompson Siegel & Walmsley's Kindred Biosciences, Inc. position peaked at $278K in Q2 2014.
  • 64 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2014.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2014, filed 9 Feb 2015.